 |
Medscape InDiscussion: DyslipidemiaAuthor: Medscape
Join Dr Laurence Sperling for "Medscape InDiscussion: Dyslipidemia," a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/958283). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Language: en Genres: Health & Fitness, Medicine, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Recent Clinical Advances in Reducing Risk for Dyslipidemia
Tuesday, 15 February, 2022
In this episode, host Dr. Laurence Sperling speaks with Drs Erin Michos and Peter Toth about optimal use of newer dyslipidemia therapies. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/958749). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources Cholesterol Treatment Trial: Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-analysis Of Data From 170,000 Participants in 26 Randomised Trials https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988224/ IMPROVE-IT: Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes https://www.nejm.org/doi/full/10.1056/nejmoa1410489 ODYSSEY: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome https://www.nejm.org/doi/full/10.1056/nejmoa1801174 FOURIER: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk -- FOURIER https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2017/03/16/00/46/FOURIER Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.037184 ORION: Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol https://pubmed.ncbi.nlm.nih.gov/32187462/ CLEAR Wisdom: Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865290/ Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121276/ CLEAR Outcomes: Rationale and Design of the CLEAR-Outcomes Trial: Evaluating the Effect of Bempedoic Acid on Cardiovascular Events in Patients With Statin Intolerance https://pubmed.ncbi.nlm.nih.gov/33470195/ CLEAR Wisdom: Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination in Patients With Hypercholesterolemia and High CVD Risk Treated With Maximally Tolerated Statin Therapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865290/ Bempedoic Acid and Ezetimibe -- Better Together https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203625/ REDUCE-IT: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia https://www.nejm.org/doi/full/10.1056/nejmoa1812792 STRENGTH: Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia -- STRENGTH https://www.acc.org/latest-in-cardiology/clinical-trials/2020/11/11/21/29/strength JELIS: Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients (JELIS): A Randomised Open-Label, Blinded Endpoint Analysis https://pubmed.ncbi.nlm.nih.gov/17398308/ PROMINENT: Rationale and Design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) Study https://pubmed.ncbi.nlm.nih.gov/30342298/ How Low Is Safe? The Frontier of Very Low (< 30 mg/dL) LDL Cholesterol https://pubmed.ncbi.nlm.nih.gov/33463677/ Cholesterol: The Race to the Bottom https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehab446/6335767?searchresult=1 SPARCL: High-Dose Atorvastatin After Stroke or Transient Ischemic Attack https://www.nejm.org/doi/full/10.1056/nejmoa061894 EBBINGHAUS: Cognitive Function in a Randomized Trial of Evolocumab https://www.nejm.org/doi/full/10.1056/nejmoa1701131 PROSPER: Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): A Randomized Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)11600-X/fulltext Achievement of Very Low Low-Density Lipoprotein Cholesterol Levels https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.119.044275
